SNPHF Stock - Santen Pharmaceutical Co., Ltd.
Unlock GoAI Insights for SNPHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $300.00B | $301.96B | $279.04B | $266.26B | $249.60B |
| Gross Profit | $171.03B | $178.71B | $166.09B | $156.59B | $151.38B |
| Gross Margin | 57.0% | 59.2% | 59.5% | 58.8% | 60.6% |
| Operating Income | $46.88B | $38.54B | $-3,090,000,000 | $35.89B | $37.80B |
| Net Income | $36.26B | $26.64B | $-14,948,000,000 | $27.22B | $6.83B |
| Net Margin | 12.1% | 8.8% | -5.4% | 10.2% | 2.7% |
| EPS | $103.98 | $72.59 | $-38.58 | $68.07 | $17.10 |
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Visit WebsiteEarnings History & Surprises
SNPHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.14 | $0.00 | -99.2% | ✗ MISS |
Q2 2025 | May 13, 2025 | $0.12 | $0.18 | +53.9% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $0.00 | $0.17 | +13975.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.18 | $0.15 | -17.2% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $0.16 | $0.20 | +23.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.10 | $0.00 | -97.9% | ✗ MISS |
Q1 2024 | Feb 8, 2024 | $0.10 | $0.14 | +29.4% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.18 | $0.16 | -13.6% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $0.14 | $0.20 | +35.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $0.02 | $0.02 | +24.9% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $0.11 | $0.11 | +6.6% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.07 | $-0.51 | -867.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.15 | $0.15 | -3.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $0.16 | $0.15 | -5.5% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $0.13 | $0.11 | -15.0% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $0.17 | $0.15 | -8.9% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $0.16 | $0.17 | +7.1% | ✓ BEAT |
Q2 2021 | May 11, 2021 | — | $-0.33 | — | — |
Latest News
Frequently Asked Questions about SNPHF
What is SNPHF's current stock price?
What is the analyst price target for SNPHF?
What sector is Santen Pharmaceutical Co., Ltd. in?
What is SNPHF's market cap?
Does SNPHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SNPHF for comparison